Brain disorders

Optime Care Offers Patient-First Humatin Total Care Program, Maximizes Therapeutic Benefits of Humatin™ for Hepatic Encephalopathy

Retrieved on: 
火曜日, 8月 3, 2021
Practice Management, Pharmaceutical, Managed care, Health, Data management, Infectious diseases, Hospitals, Technology, Brain disorders, Medical specialties, Anatomy, Branches of biology, Hepatology, Coma, Hepatic encephalopathy, Encephalopathy, Orphan drugs, Paromomycin, Liver

Optime Care , a nationally recognized pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, announces the availability of Humatin (paromomycin sulfate) exclusively through Humatin Total Care .

Key Points: 
  • Optime Care , a nationally recognized pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, announces the availability of Humatin (paromomycin sulfate) exclusively through Humatin Total Care .
  • Humatin Total Care enables physicians to maximize the therapeutic opportunity for treating hepatic encephalopathy.
  • In the most severe form of hepatic encephalopathy, affected individuals may develop marked confusion or disorientation, amnesia, stupor or coma.
  • Quill concludes, As part of our patient-first focus, Humatin Total Care helps every stakeholder group impacted by this disease.

The Evolution of Blood Purification Technologies to Treat Emerging Pandemic Threats, Including COVID-19

Retrieved on: 
月曜日, 6月 28, 2021
Anatomy, Organs anatomy), Health sciences, Brain disorders, Hepatology, Organ failure, Coma, Hepatic encephalopathy, Liver, Encephalopathy, Therapy

Mr. Joyce will review the congressional effort that expanded Project BioShield to be inclusive of blood purification devices and will additionally discuss how COVID-19 has unveiled the ability of blood purification therapies to deliver life-saving mechanisms that are beyond the reach of post-infection drugs.

Key Points: 
  • Mr. Joyce will review the congressional effort that expanded Project BioShield to be inclusive of blood purification devices and will additionally discuss how COVID-19 has unveiled the ability of blood purification therapies to deliver life-saving mechanisms that are beyond the reach of post-infection drugs.
  • Note: In addition to co-founding Sigyn Therapeutics, Mr. Joyce was the founder of Aethlon Medical and oversaw the development of the Aethlon Hemopurifier.
  • The Company is also conducting studies to evaluate the potential use of Sigyn Therapy to treat acute forms of liver failure, including hepatic encephalopathy.
  • However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021

Retrieved on: 
月曜日, 5月 24, 2021
Research, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Medical specialties, Hepatitis, Clinical medicine, Brain disorders, Anatomy, Hepatology, Encephalopathy, Hepatic encephalopathy, Steatohepatitis, Non-alcoholic fatty liver disease

These included a statistically significant change in the psychometric hepatic encephalopathy score (PHES) for patients receiving the 53.8 g dose of AXA1665 versus placebo.

Key Points: 
  • These included a statistically significant change in the psychometric hepatic encephalopathy score (PHES) for patients receiving the 53.8 g dose of AXA1665 versus placebo.
  • The DDW oral presentation included new subject-level data in certain measures of neurocognition and muscle function.
  • A video recording of Dr. Sanyals presentation at DDW 2021 is now available in the Publications section of Axcellas website at https://axcellahealth.com/publications/ .
  • Axcellas pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence.

Axcella to Report First Quarter 2021 Financial Results on May 6, 2021

Retrieved on: 
火曜日, 4月 27, 2021
Health, Biotechnology, Brain disorders, Medical specialties, Anatomy, Hepatology, Clinical medicine, Coma, Hepatic encephalopathy, Encephalopathy, Steatohepatitis, Ohe

b'Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its first quarter 2021 financial results and other business updates on May 6, 2021.

Key Points: 
  • b'Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its first quarter 2021 financial results and other business updates on May 6, 2021.
  • ET that morning.\nThe conference call webcast will be available in the Investors & News section on the company\xe2\x80\x99s website at www.axcellahealth.com .
  • To access the call via telephone, please dial (844) 808-7139 (U.S. toll free) or (412) 902-0127 (international) five minutes prior to the start time.
  • Axcella\xe2\x80\x99s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence.

Axcella Announces Upcoming Oral Presentation at Digestive Disease Week (DDW) 2021

Retrieved on: 
木曜日, 4月 22, 2021
Health, Other Health, Other Science, Clinical trials, Research, Science, Biotechnology, Medical specialties, Hepatitis, Brain disorders, Clinical medicine, Anatomy, Hepatology, Steatohepatitis, Hepatic encephalopathy, Non-alcoholic fatty liver disease, Nash, Encephalopathy, Endogenous Metabolic Modulators (EMMs), Axcella, ENDOGENOUS METABOLIC MODULATORS (EMMS), AXCELLA

Abstracts are expected to appear on DDW\xe2\x80\x99s website in late April and in the May online supplement to Gastroenterology.

Key Points: 
  • Abstracts are expected to appear on DDW\xe2\x80\x99s website in late April and in the May online supplement to Gastroenterology.
  • ePosters and ePapers will be made available on this website during the congress.
  • The company\xe2\x80\x99s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways.
  • Axcella\xe2\x80\x99s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence.

New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio

Retrieved on: 
木曜日, 4月 8, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical trials, Other Health, Brain disorders, Rare diseases, Monoclonal antibodies, Medical specialties, Branches of biology, Clinical medicine, Progressive multifocal leukoencephalopathy, Ocrelizumab, PML, Leukoencephalopathy, spinal muscular atrophy, Evrysdi™ (risdiplam), multiple sclerosis, Ocrevus, neuromyelitis optica spectrum disorder, Enspryng™ (satralizumab-mwge), Genentech in neuroscience, Genentech

If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.

Key Points: 
  • If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.
  • Progressive Multifocal Leukoencephalopathy (PML): Although no cases have been seen with Ocrevus treatment in clinical trials, PML may happen with Ocrevus.
  • Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms.
  • These may include problems with thinking, balance, eyesight, weakness on 1 side of your body, strength, or using your arms or legs.

Global Hepatic Encephalopathy Market to Surpass US$ 511.6 Million by 2027, Says Coherent Market Insights (CMI)

Retrieved on: 
火曜日, 3月 30, 2021
General Health, Pharmaceutical, Health, Brain disorders, Medical specialties, Hepatology, Encephalopathy, Hepatic encephalopathy, Liver, Clinical medicine

According to Coherent Market Insights, the global hepatic encephalopathy market is estimated to be valued at US$ 355.4 million in 2020 and is expected to exhibit a CAGR of 5.3% during the forecast period (2020-2027).

Key Points: 
  • According to Coherent Market Insights, the global hepatic encephalopathy market is estimated to be valued at US$ 355.4 million in 2020 and is expected to exhibit a CAGR of 5.3% during the forecast period (2020-2027).
  • Key trends in the market include increasing prevalence of hepatic encephalopathy, increasing research and development activities, and others.
  • Market players are indulged in conducting clinical trials, in order to develop treatment for hepatic encephalopathy.
  • Among regions, North America is expected to hold a dominant position in the global hepatic encephalopathy market over the forecast period, owing to increasing prevalence of hepatic encephalopathy in this region.

Coastline’s Acquired Brain Injury (ABI) Program is partnering with Brain Strategies & Technology (BEST) and Global Brain Injury Awareness (GBIA) to Celebrate Brain Injury Awareness Month

Retrieved on: 
水曜日, 3月 3, 2021
Neurotrauma, Brain disorders, Branches of biology, Medical specialties, Medical emergencies, Nervous system, Brain damage, Acquired brain injury, Injury

Coastline Colleges Acquired Brain Injury (ABI) Program is partnering with Brain Education Strategies & Technology (BEST) and Global Brain Injury Awareness (GBIA) to help spread awareness, using social media (@coastlineabiprogram, @coastlineabi, @bestbrainorg, @global_bia), to reach a global audience.

Key Points: 
  • Coastline Colleges Acquired Brain Injury (ABI) Program is partnering with Brain Education Strategies & Technology (BEST) and Global Brain Injury Awareness (GBIA) to help spread awareness, using social media (@coastlineabiprogram, @coastlineabi, @bestbrainorg, @global_bia), to reach a global audience.
  • has scheduled a virtual Brain Injury Awareness Day briefing for Wednesday, March 3, 2021 from 2-4 p.m. (ET).
  • An acquired brain injury (ABI) is any injury to the brain that is not hereditary, congenital, degenerative, or induced by birth trauma.
  • They provide information about brain injury to help survivors, their families, and caregivers understand what has happened to a person with a brain injury.

Progressive Multifocal Leukoencephalopathy Pipeline Review, H2 2020 Report - Therapeutics Development and Assessment, Drug Profiles, Dormant Projects, Development Milestones, Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
火曜日, 1月 12, 2021
Health, Pharmaceutical, Brain disorders, Leukoencephalopathy, Medical specialties, Branches of biology, Progressive multifocal leukoencephalopathy, Clinical medicine, PMLE

Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Key Points: 
  • Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Hepatic Encephalopathy Pipeline Review, H2 2020: Therapeutic Analysis of 12 Companies & 2 Drug Profiles - ResearchAndMarkets.com

Retrieved on: 
火曜日, 9月 29, 2020
Health, General Health, Brain disorders, Anatomy, Medical specialties, Hepatology, Coma, Hepatic encephalopathy, RTT, Encephalopathy, Liver, Organ systems

Hepatic Encephalopathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Key Points: 
  • Hepatic Encephalopathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Hepatic Encephalopathy (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide reviews key companies involved in Hepatic Encephalopathy (Gastrointestinal) therapeutics and enlists all their major and minor projects.